Ostalo

LIVER TRANSPLANTATION IN HEPATITIS B VIRAL INFECTION

TAJANA FILIPEC KANIŽAJ ; Klinička bolnica Merkur, Medicinski fakultet Sveučilišta u Zagrebu, Klinika za unutarnje bolesti, Zavod za gastroenterologiju, Zagreb, Hrvatska
VESNA ČOLIĆ-CVRLJE ; Klinička bolnica Merkur, Medicinski fakultet Sveučilišta u Zagrebu, Klinika za unutarnje bolesti, Zavod za gastroenterologiju, Zagreb, Hrvatska
ANNA MRZLJAK ; Klinička bolnica Merkur, Medicinski fakultet Sveučilišta u Zagrebu, Klinika za unutarnje bolesti, Zavod za gastroenterologiju, Zagreb, Hrvatska
RAJKO OSTOJIĆ ; Klinički bolnički centar Zagreb, Medicinski fakultet Sveučilišta u Zagrebu, Klinika za unutarnje bolesti, Zavod za gastroenterologiju, Zagreb, Hrvatska

Sažetak

Hepatitis B infection (HBV) causes liver cirrhosis and hepatocellular carcinoma that are indications for orthotopic liver transplantation (OLT). The outcome of OLT depends on the prevention of HBV reinfection and disease relapses. Out of 692 liver transplantations performed at Merkur University Hospital, 30 were done for HBV infection. These patients were treated with HBIG post OLT and lamivudine, entecavir, adefovir, tenofovir prior and post OLT. All patients became HBsAg and HBV DNA negative but four of them became HbsAg positive one year post OLT. The patients survived for 2 months to 7 years post OLT. With the introduction of HBIG immunoprophylaxis and new efficient antiviral treatment, the risk of relapse is only <10%, and survival is the same as in other indications for OLT. Because of the high cost and long-term treatment, efforts have been made to prevent recurrent HBV disease by using the schedules according to pre- and post-transplant HBV viremia and introducing the new potent antiviral analogue nucleos(t)ides.

Ključne riječi

liver transplantation; HBV immunoprophylaxis; hepatitis B immunoglobulin; nucleos(t)ide analogues

Hrčak ID:

113725

URI

https://hrcak.srce.hr/113725

Datum izdavanja:

14.1.2014.

Podaci na drugim jezicima: hrvatski

Posjeta: 1.633 *